NASDAQ · OPK
OPKO Health, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OPK: Nov 04, 2026
OPKO Health, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $0.03.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.07 | $-0.06 | $-0.08 | 5 |
| Dec 2026 | $-0.08 | $-0.06 | $-0.10 | 5 |
| Mar 2027 | $-0.07 | $-0.06 | $-0.08 | 5 |
| Jun 2027 | $-0.07 | $-0.06 | $-0.07 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks- Zacks · Oct 29, 12:24 PM EDTReasons to Hold Hinge Health Stock in Your Portfolio for NowHNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
- Zacks · Oct 29, 10:48 AM EDTBaxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook RaisedBAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.
- Zacks · Oct 28, 10:05 AM EDTGEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View RaisedGE HealthCare's Q3 earnings and revenues beat estimates on strong segment growth and higher margins, driving raised 2026 guidance as shares gain 8.3%.
- Zacks · Oct 28, 8:37 AM EDTCencora to Acquire AON in $2.4B Deal to Expand Oncology NetworkCOR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.
- Zacks · Oct 27, 1:30 PM EDTEcolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/YECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital sales.
- Zacks · Oct 27, 1:29 PM EDTHere's Why You Should Hold PacBio Stock in Your Portfolio for NowPACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
- Zacks · Oct 27, 11:31 AM EDTWaters & Labcorp Expand Access to FDA-Approved HPV Screening TestsWAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.
- Zacks · Oct 23, 11:19 AM EDTSOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.TherapySolventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.
- Zacks · Oct 23, 9:55 AM EDTFMS Launches multiFiltratePRO System for U.S. Patients With Acute AKIFresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
- Zacks · Oct 22, 9:42 AM EDTGEHC Expands Theranostics Imaging With 5 Global CollaborationsGE HealthCare expands its theranostics imaging push with five global collaborations to evaluate StarGuide GX, targeting advances in precision oncology and nuclear medicine.
- Zacks · Oct 22, 9:34 AM EDTRevvity Launches Signals LabGistics to Coordinate Scientific WorkflowsRVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
- Zacks · Oct 21, 7:14 AM EDTStryker's Sonopet 3 Secures FDA Clearance to Improve Surgical AccuracySYK's Sonopet 3 secures FDA clearance, promising enhanced surgical precision and efficiency, with a full commercial launch expected later this fall.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for OPKO Health, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.